{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.3","upperLimit":"13.5","value":"8.90"},{"groupId":"OG003","lowerLimit":"49.1","upperLimit":"49.1","value":"49.10"},{"groupId":"OG004","lowerLimit":"19.4","upperLimit":"35.2","value":"27.20"},{"groupId":"OG005","lowerLimit":"14.1","upperLimit":"14.1","value":"14.10"},{"groupId":"OG006","lowerLimit":"23.0","upperLimit":"39.0","value":"32.55"},{"groupId":"OG007","lowerLimit":"25.6","upperLimit":"48.8","value":"32.10"},{"groupId":"OG008","lowerLimit":"8.5","upperLimit":"45.3","value":"21.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"title":"Day 1; n=2,0,0,1,3,1,10,10,7"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"46.5","value":"46.50"},{"groupId":"OG001","lowerLimit":"36.8","upperLimit":"36.8","value":"36.80"},{"groupId":"OG003","lowerLimit":"39.7","upperLimit":"39.7","value":"39.70"},{"groupId":"OG004","lowerLimit":"25.7","upperLimit":"29.1","value":"27.40"},{"groupId":"OG005","lowerLimit":"23.0","upperLimit":"33.8","value":"26.85"},{"groupId":"OG006","lowerLimit":"12.2","upperLimit":"65.7","value":"30.00"},{"groupId":"OG007","lowerLimit":"8.2","upperLimit":"38.3","value":"25.70"},{"groupId":"OG008","lowerLimit":"15.1","upperLimit":"40.3","value":"30.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"9"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"4"}],"units":"Participants"}],"title":"Day 15; n=1,1,0,1,2,4,9,11,4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"description":"Blood samples were collected from participants for pharmacokinetic analysis including T1/2 following single (Day 1) and repeat dose (Day 15) administration of GSK2816126. Pharmacokinetic analysis of GSK2816126 in Part 1 was conducted by non-compartmental methods. Pharmacokinetic parameter derivation for some participants did not strictly conform to the prescribed acceptance criteria and hence data was not available for those participants. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).","dispersionType":"Full Range","groups":[{"description":"Eligible participants received GSK2816126 with a starting dose of 50 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG000","title":"Part 1:GSK2816126 50 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG001","title":"Part 1:GSK2816126 100 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG002","title":"Part 1:GSK2816126 200 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG003","title":"Part 1:GSK2816126 400 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG004","title":"Part 1:GSK2816126 800 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG005","title":"Part 1:GSK2816126 1200 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG006","title":"Part 1:GSK2816126 1800 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG007","title":"Part 1:GSK2816126 2400 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG008","title":"Part 1:GSK2816126 3000 mg Twice-weekly"}],"paramType":"MEDIAN","populationDescription":"Pharmacokinetic Population","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, (12, 18 on Day 1 only), 24, and 96 hours post-dose from start of infusion; 0.5, 1, 2, 4, 6 hours from end of infusion on Cycle 1 of Day 1 and Day 15 (Each cycle was of 28 days)","title":"Part 1: Apparent Terminal Phase Half-life (T1/2) Following Single and Repeat Dose Administration of GSK2816126","type":"SECONDARY","unitOfMeasure":"Hours"}